Amanta Healthcare IPO Date, Review, Price and Key Information

Amanta Healthcare Limited IPO is fully book build issue and it is fully fresh issue. The total offering consists of 1,25,000,00 fresh shares.

The dates for the Amanta Healthcare IPO have not been announced yet.

The allotment process is expected to be finalized by [.]. The Amanta Healthcare IPO is scheduled to list on BSE, NSE, with a tentative listing date of [.].

The price band for the Amanta Healthcare IPO has not been announced yet.

Registrar for this IPO is MUFG Intime India Private Limited and lead managers for Amanta Healthcare IPO are Beeline Capital Advisors Private Limited.

IPO Schedule

IPO Open Date	-
IPO Close Date	-
IPO Allotment Date	-
Refund Initiation	-
Share credit in Demat	-
Listing Date	-

Key Details

Price Band	TBA
Lot Size	TBA
Face Value	₹10 Per Equity Share
Total Issue Size	12,500,000 Shares
Fresh Issue	12,500,000 Shares
Issue Type	Fresh Issue and Offer for Sale
Listing At	BSE, NSE

Share Reservation

Investor Category	Shares Offered
QIB	50%
Retail	35%
NII/HNI	15%

About Amanta Healthcare Limited Company

Amanta Healthcare Limited is a pharmaceutical company specializing in sterile liquid products, including Large Volume Parenterals (LVPs) and Small Volume Parenterals (SVPs). These products are manufactured using Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) technologies.

The company offers a diverse range of products across six therapeutic segments, including fluid therapy, formulations, diluents, ophthalmic, respiratory care, and irrigation solutions. Additionally, they manufacture medical devices like irrigation solutions and eye lubricants. Amanta Healthcare caters to various needs with container fill-volumes ranging from 2ml to 1000ml.

Amanta Healthcare markets its products through national sales, international sales, and product partnering. They manufacture over 45 generic products under their brands in India, supported by a network of over 316 distributors and stockists. The company exports branded products to 19 countries. Their revenue from operations witnessed a growth of 8.19% from fiscal year 2023 to 2024, reaching ₹280.34 million. The total income for the fiscal year 2024 was ₹281.60 million and EBITDA stood at ₹58.75 million.

Their manufacturing facility holds GMP certifications, ensuring quality. With a dedicated F&D and quality control laboratory, Amanta Healthcare focuses on continuous improvement and innovation in formulations.

Amanta Healthcare Limited Financial Details

Period Ended	31 Dec 2024	31 Mar 2024	31 Mar 2023	31 Mar 2022
Assets	3797.05	3521.20	3740.61	3792.77
Revenue	202.65	280.34	259.13	225.44
Profit After Tax	45.42	36.23	-21.11	538.82
Net Worth	905.84	662.89	628.83	649.72
Reserves and Surplus	617.54	394.59	360.54	381.43
Total Borrowing	1965.88	2052.29	2156.58	2216.24

₹ In Crore

Key Performance Indicator

Basic EPS (in ₹)	Return on Net Worth (RoNW)	Net Asset Value (NAV)	Debt-Equity Ratio	Return on Equity (ROE)	Return on Capital Employed (ROCE)
1.35	5.48%	24.71

Offer Objectives

The document outlines details regarding the transfer of equity shares, acquisitions, and the objects of the company's issue. Numerous equity share transfers occurred between 2008 and 2025, with face values of ₹10 per share, primarily for cash consideration at varying prices.

Notable transfers include transactions involving Bhupendra Gor, Harikrishna C. Patel, and American Mannequines INC, among others. Some transactions are marked as gifts. Bhavesh Patel acquired shares through gifts and purchases at ₹10 and ₹100.

The company plans to issue up to 1,25,00,000 equity shares to raise funds for setting up new SteriPort and SVP manufacturing lines in Hariyala, Kheda, Gujarat, and for general corporate purposes. A total of ₹7,000 lakhs (₹70 Crore) will be allocated for SteriPort and ₹3,013.30 lakhs (₹30.133 Crore) for SVP. The amount for general corporate purposes is to be determined but will not exceed 25% of the gross proceeds.

The schedule for deployment of the Net Proceeds indicates that by December 31, 2024, ₹967.43 lakhs (₹9.6743 Crore) had been deployed. The estimated deployment for fiscal year 2025 is ₹6,300 lakhs (₹63 Crore) for SteriPort and ₹1,500 lakhs (₹15 Crore) for SVP, with remaining amounts planned for fiscal year 2026.